News
Market and company headlines
TMOAll
Loading
10:00Yesterday2 Stories
Global DNA Sequencing in Drug Discovery Market Report 2026 | Capitalize on 12.5% CAGR as Illumina, Thermo Fisher, QIAGEN, and Oxford Nanopore Accelerate AI-Driven Precision R&D
Boost ROI through lower-cost assays, AI-driven analysis, local consumables production, supplier diversification, multiomics, and pharma-biotech partnerships.Dublin, Oct. 26, 2026 (GLOBE NEWSWIRE) -- "Deoxyribonucleic Acid (DNA) Sequencing in Drug Discovery Market Report 2026" has been added to ResearchAndMarkets.com's offering. DNA Sequencing in Drug Discovery Market to Reach $15.22 Billion by 2030 as Precision Medicine Advances The global deoxyribonucleic acid (DNA) sequencing in drug discovery
Cell and Gene Therapy Contract Research Organization Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, IQVIA, Labcorp, ICON, and WuXi AppTec Scale Integrated Trials
Boost ROI by outsourcing R&D, integrating preclinical and clinical services, leveraging data-driven trials, strengthening compliance, and localizing labs to reduce tariff costs.Dublin, Oct. 26, 2026 (GLOBE NEWSWIRE) -- "Cell and Gene Therapy Contract Research Organization Market Report 2026" has been added to ResearchAndMarkets.com's offering. Cell and Gene Therapy Contract Research Organization Market to Reach $12.36 Billion by 2030 The global cell and gene therapy contract research organizatio
12:00-14:00Oct 232 Stories
Should Illumina Stock Holders Look At Thermo Fisher Instead?
For questions about this article or underlying research, email help@trefis.com.
Thermo Fisher Scientific (TMO) Benefits on Broad-Based Recovery Across Life-Science Markets
Broyhill Asset Management, a Charlotte-based firm, issued its third-quarter 2026 investor letter. The letter can be downloaded here. The Broyhill Equity Composite decreased by 0.3% in Q3, underperforming the MSCI All Country World Index, which gained 1.7%. For the first nine months of the year, the Composite returned 1.9%, compared to 13.4% for the Index. The […]
10:00Oct 232 Stories
Citigroup Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $800
Citigroup analyst Patrick Donnelly maintains Thermo Fisher Scientific (NYSE:TMO) with a Buy and raises the price target from $685 to $800.
NGS Kits Market Forecasts Growth from $6.84 Billion (2025) to $19.36 Billion by 2036, Profiling Illumina, Thermo Fisher Scientific, Roche, Oxford Nanopore & 11 Other Key Players
201-Page Report Finds Library Preparation Leads and Long-Read Sequencing Grows Fastest as Clinical Oncology Testing and Genomics Programs Expand, While Fragmented Reimbursement and Lab Capacity Limits Slow AdoptionDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "NGS Kits Market: Focus on Workflow, Sequencing Type, Application, End User, and Regional Analysis - Analysis and Forecast Year, 2026-2036" has been added to ResearchAndMarkets.com's offering. The global NGS kits market was valued at $6,843.4 m
08:00Oct 222 Stories
Barclays Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $775
Barclays analyst Luke Sergott maintains Thermo Fisher Scientific (NYSE:TMO) with a Overweight and raises the price target from $750 to $775.
RBC Capital Maintains Sector Perform on Thermo Fisher Scientific, Raises Price Target to $730
RBC Capital analyst Dan Leonard maintains Thermo Fisher Scientific (NYSE:TMO) with a Sector Perform and raises the price target from $580 to $730.
05:00-07:00Oct 222 Stories
TD Cowen Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $810
TD Cowen analyst Dan Brennan maintains Thermo Fisher Scientific (NYSE:TMO) with a Buy and raises the price target from $760 to $810.
Stifel Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $775
Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:TMO) with a Buy and raises the price target from $650 to $775.
03:00-05:00Oct 222 Stories
TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
Life sciences company Thermo Fisher (NYSE:TMO) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $12.14 billion. Its non-GAAP profit of $6.68 per share was 4.3% above analysts’ consensus estimates.
Baird Maintains Outperform on Thermo Fisher Scientific, Raises Price Target to $756
Baird analyst Catherine Schulte maintains Thermo Fisher Scientific (NYSE:TMO) with a Outperform and raises the price target from $723 to $756.
02:00Oct 221 Story
15:00-17:00Oct 213 Stories
Thermo Fisher Scientific Inc. Reports Third Quarter 2026 Results
Thermo Fisher Stock Shrugs Off a Beat: Here’s What It Looks Like Without Tariff Refunds
Thermo Fisher Scientific (TMO:NYSE) beat Wall Street’s third-quarter estimates on Wednesday, October 21, and the stock barely moved. Shares were up about 1% at roughly $695 in afternoon trading.
12:00-14:00Oct 212 Stories
09:00-11:00Oct 213 Stories
Thermo Fisher Scientific Q3 Earnings Call Highlights
Thermo Fisher Scientific (NYSE:TMO) reported third-quarter revenue growth of 9% to $12.14 billion, supported by 6% organic growth, acquisitions and foreign-exchange effects. Adjusted earnings per share rose 15% to $6.68, while adjusted operating income increased 15% to $2.97 billion. Chairman and C
Thermo Fisher Scientific Reports 9% Revenue Growth as Third-Quarter Earnings Beat Estimates
Thermo Fisher Scientific (NYSE:TMO) reported third-quarter 2026 earnings and revenue above analysts’ expectations on Wednesday, supported by growth in its laboratory products and services business and an improvement in operating margins. The US life sciences and laboratory equipment company posted adjusted earnings per share of $6.
08:00Oct 213 Stories
Thermo Fisher Slides Despite Third-Quarter Beat — Here's What Happened
Thermo Fisher stock fell early Wednesday as its miss in life sciences overshadowed an otherwise solid third-quarter report.
TMO Q3 Earnings & Revenues Beat Estimates, Stock Down in Pre-Market
Thermo Fisher beats Q3 earnings and revenue estimates, with double-digit profit growth and wider margins, yet shares fall 4.1% in pre-market trading.
06:00-08:00Oct 214 Stories
Thermo Fisher Scientific (NYSE:TMO) Posts Q3 Earnings Beat With In-Line Revenue
Thermo Fisher Q3 2026 results: adjusted EPS beat consensus, revenue in line; margin expansion and strong free cash flow support a solid operating quarter.
Thermo Fisher beats profit, revenue expectations in Q3
Investing.com -- Thermo Fisher Scientific on Wednesday reported third-quarter profit and revenue above analyst estimates.
04:00Oct 212 Stories
Global Bioprocessing Reagent Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, Danaher, Merck KGaA and Sartorius Accelerate AI and Single-Use Systems
Boost ROI via single-use systems, AI optimization and continuous processing to cut capital costs, contamination and downtime while improving yield, scalability and efficiency.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Bioprocessing Reagent Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global bioprocessing reagent market is experiencing rapid expansion, driven by rising biologics production, increased vaccine manufacturing, and continued investment in pharmaceutical
Global Human Osteoblasts Market Report 2026 | Capitalize on $53.09 Billion Revenue Share by 2030 as Merck KGaA, Thermo Fisher Scientific, Lonza and STEMCELL Lead the Industry
Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Human Osteoblasts Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global human osteoblasts market is experiencing strong growth, supported by the rising prevalence of bone-related diseases, an expanding geriatric population, and increased investment in regenerative medicine and bone tissue engineering. The market is projected to grow from $35.81 billion in 2025 to $38.68 billion in 2026, representing a compound annual growth
02:00-12:00Oct 202 Stories
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings
Thermo Fisher reports Q3 earnings Oct. 21, with analysts expecting $6.40 EPS and $11.93B revenue; analysts remain bullish, raising price targets.
01:00Oct 201 Story
06:00Oct 191 Story
17:00-00:00Oct 162 Stories
Thermo Fisher Scientific (TMO) Is Building A Bigger Role In Precision Diagnostics
Thermo Fisher Scientific (NYSE:TMO) is expanding its presence in proteomic biomarker analytics and immuno-oncology diagnostics, according to recent industry reports. Sector intelligence points to the group as a key provider of targeted omics and biomarker analytics solutions for precision medicine-focused projects. Reports also highlight Thermo Fisher's role in immuno-oncology diagnostic workflows that support more tailored cancer treatment decisions. Thermo Fisher's push into proteomic...
Thermo Fisher Scientific (TMO) Stock Gets Fair Value Bump After Q2 Driven Analyst Target Increases
Thermo Fisher Scientific’s fair value estimate has shifted from US$652.85 to US$686.64, pointing to a modestly higher price target in current models. Recent analyst commentary ties this change to more supportive views on Q2 results, sector demand trends and updated company guidance, even as opinions remain split between bullish and more cautious takes. As you read on, you will see how this evolving narrative fits together and what to watch next as new research comes out. Analyst Price Targets...
12:00-14:00Oct 162 Stories
Learn Why The Bull Case For Thermo Fisher Scientific Stock Could Change Following Omics Demand Growth
Quantum BioPharma previously announced a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business for a Phase 2 Lucid-MS trial. Thermo Fisher also rolled out new drug development and cell culture solutions and expanded real-world evidence capabilities across oncology and immunology. Thermo Fisher Scientific now sits at the intersection of rising demand for omics, biomarker analytics, and outsourced clinical research services. This trend concentrates more workflow,...
Thermo Fisher Scientific Outperforms on Strong Results and Life Sciences Recovery
Diamond Hill Capital, a First Eagle Investment Management company, issued its Q3 2026 investor letter for its “Large Cap Strategy”. The letter can be downloaded here. The Strategy returned 3.18% (net of fees) in the quarter, outperforming the 2.61% return of the Russell 1000 Value Index. Key positive contributors included stock selection in information technology, an underweight in […]
08:00-12:00Oct 162 Stories
Academic and Government Spending Powers Thermo Fisher (TMO)
Emerald Wealth Partners, an independent asset and wealth management firm based in Zurich, released its Q3 2026 investor letter for the “Focused Equity Strategy.” The letter can be downloaded here. The Focused Equity Strategy returned 8.9% gross and 8.7% net in Q3, amid a dynamic investment environment driven by AI infrastructure development. Following an initial […]
What Analyst Projections for Key Metrics Reveal About Thermo Fisher (TMO) Q3 Earnings
Besides Wall Street's top-and-bottom-line estimates for Thermo Fisher (TMO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
03:00-08:00Oct 162 Stories
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Thermo Fisher: Strong Growth, Even Higher Stock Price
Thermo Fisher Scientific remains overvalued despite strong Q2/26 results and a 30% stock rally since the last review. I rate the TMO stock a Hold. Read my analysis now.
09:00Oct 142 Stories
Final Trades: Thermo Fisher, Pfizer, U.S. 10-year and the XAR
The Investment Committee gives you their top stocks to watch for the second half.
Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04:00Oct 144 Stories
Single-Use Assemblies Global Market Report 2026-2030 | Capitalize on 22.8% CAGR as Thermo Fisher, Danaher, Sartorius, Merck, and Avantor Scale Modular Bioprocessing
Boost ROI with modular, customized systems that scale flexibly, cut cleaning and contamination costs, speed fill-finish, and localize sourcing to reduce tariff and supply-chain risks.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Single-Use Assemblies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global single-use assemblies market is experiencing rapid growth, driven by expanding biopharmaceutical manufacturing, increased investment in life sciences research and devel
Global Metabolomics Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 17.3% CAGR as Thermo Fisher, Bruker, Agilent, and Metabolon Accelerate AI Diagnostics
Players: Metabolon, Bruker, Agilent, Thermo Fisher and Waters. Profiles cover products, services, market share, segments, trends, opportunities and regional presence.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Metabolomics Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global metabolomics market is experiencing rapid expansion, driven by advances in biomarker discovery, personalized medicine, cancer research and analytical technologies. The market grew from $4.17 bil
06:00Oct 51 Story
04:00-12:00Oct 13 Stories
Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026: Market to Surge to $21.46 Billion by 2030 as Thermo Fisher Scientific, Merck KGaA, Lonza and Samsung Biologics Accelerate Automation
Boost ROI with scalable viral-vector platforms, automated single-use processing, digital quality control, and expanded CDMO capacity through partnerships and acquisitions.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell and gene therapy biomanufacturing market is experiencing rapid expansion as advanced therapies move from research and clinical development toward comm
Biomarkers Market Forecasts Growth from $67.95B (2026) to $112.10B by 2031, Profiling Roche, Abbott, Thermo Fisher & Qiagen
The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, registering a 10.5% CAGR. Growth is driven by precision medicine, companion diagnostics, AI, bioinformatics, digital pathology and multi-omics technologies. Predictive biomarkers led the efficacy segment in 2025, while immunoassays held the largest technology share. Asia Pacific is forecast to be the fastest-growing region. Key players include Roche, Abbott, Thermo Fisher Scientific, Q
04:00-10:00Sep 302 Stories
Recombinant Proteins Market - Global Strategic Business Report: Sales Hit to $5.8 Billion by 2030 - Benchmark Thermo Fisher Scientific, Merck KGaA, Amgen, Bio-Techne and GenScript Biotech Amid Tariff Disruption
Demand for biologics, targeted therapies and personalized medicine is rising, while AI-led protein design and scalable bioprocessing unlock new opportunities.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global recombinant proteins market was valued at US$3.3 billion in 2024 and is projected to reach US$5.8 billion by 2030, expanding at a compound annual growth rate of 10.2%. Ma
Fetal Bovine Serum Market Outlook 2026-2035 - Featuring Profiles of Leading Companies Thermo Fisher Scientific, Merck KGaA, and Cytiva
Fetal Bovine Serum Market Gains Momentum as Stem Cell Research, Vaccine Innovation and Advanced Therapies Drive Demand for High-Quality, Ethically Sourced ProductsDublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Fetal Bovine Serum Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. The global fetal bovine serum market was valued at USD 1.1 billion in 2025 and is projected to reach USD 2.3 billion by 2035, expanding
02:00Sep 291 Story
21:00Sep 282 Stories
Thermo Fisher (TMO) Is Turning Innovation Into Recurring Revenue. Can Margins Follow?
On September 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel enables […]
Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative
Earlier this month, Thermo Fisher Scientific announced several product and collaboration updates, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep’s Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and Memorial Sloan Kettering. Together, these moves deepen Thermo Fisher’s role across biologics manufacturing, advanced proteomics, and ctDNA-based cancer...
05:00-09:00Sep 282 Stories
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
WALTHAM, Mass., September 28, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2026 before the market opens on Wednesday, October 21, 2026, and will hold a conference call on the same day at 7:00 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations.
Global Cell Line Generation Market Outlook, 2026-2032 - AI, CRISPR and Automation Fuel 10.86% CAGR, Driving the Market to USD 2.67 Billion as Thermo Fisher Scientific, Lonza, Merck and WuXi Biologics Advance Innovation
Boost ROI through standardized QC, auditable automation, validated AI, diversified reagent sourcing, regional partnerships, and cross-skilled workforce trainingDublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Cell Line Generation Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global cell line generation market, which is projected to reach USD 1.42 billion in 2026 and grow at a CAGR of 10.86% to USD 2.67 billion by 2032